Tirzepatide ���子背景与靶点 — Complete Guide

By Editorial Desk · published 2026-01-06 · last reviewed 2026-01-24 · Data

incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-01-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide 分子背景与靶点

在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。

Dual Incretin Receptor Pharmacology

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.

At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.

Tirzepatide at a glance

Molecular Background and Dual Receptor Action

Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.

Related pages on this site

• Practical playbook
• Reliable collection
• Material guide
• Balanced briefing
• Adaptive reference
• Seasonal casebook
• Modular review
• Lightweight checklist

Tirzepatide Pharmacology and Development History

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

Molecular Background and Receptor Pharmacology

The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Reference notes

HCO2H → H2 + CO2 Soluble ruthenium catalysts are also effective for producing carbon monoxide-free hydrogen. It is used as a source of hydrogen in transfer hydrogenation, as in the Leuckart reaction to make amines and (in aqueous solution or in its azeotrope with triethylamine) for hydrogenation of ketones.

=== Casting === In February 2025, Jessica Lange, who starred in the first four seasons and briefly appeared in the eight season in 2018, answered a question about her potential return for the thirteenth season: "Oh Christ, no. I mean, I haven't done it for more than 10 years, 12 years, so, no, I'm not doing it." Murphy revealed that Lange was the first person he turned to about the return and she agreed under the condition she would have a musical number. Subsequently, he turned to Sarah Paulson and Evan Peters, who agreed instantly. They both last appeared in the tenth season in 2021. In October 2025, Lange, Paulson, Peters, Emma Roberts, Billie Lourd, Kathy Bates, Angela Bassett, Leslie Grossman, Jessica Lange, and Gabourey Sidibe were all confirmed to return for the thirteenth season, along with the newcomer Ariana Grande. Bates, Bassett and Sibide last appeared in the eight season in 2018. Bates revealed that she would have only one day of filming. In February 2026, John Waters joined the cast, while Joey Pollari joined in April, and Alex Consani and Paul Anthony Kelly joined in May. John Carroll Lynch and Matt Fraser were also confirmed to reprise their roles from Freak Show, with Mena Suvari and Berto Colón also joining the cast. In July, Frances Conroy was confirmed to reprise her role from Coven, with Avantika, Grace Dumdaw, Cara Delevingne, and Charlie Carver also joining the cast. In July 2026, it was reported that Grande dropped out due to scheduling conflicts with the season's production schedule and her Eternal Sunshine Tour.

== External links == Histocompatibility+Antigens+Class+II at the U.S. National Library of Medicine Medical Subject Headings (MeSH) MHC+Class+II+Genes at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

Sources: en.wikipedia.org

Notes from published material

British businessmen Hamish Harding and Shahzada Dawood, along with Dawood's son, Suleman, are confirmed as being aboard the missing submersible that disappeared during a voyage to see the wreck of the RMS Titanic two days earlier. 21 June – UK inflation figures for May 2023 show it remained higher than expected, at 8.7%. 22 June The Bank of England raises the official bank rate from 4.5% to 5%, the 13th consecutive rise, and a greater increase than economists had expected. The RMT announces three fresh days of strike action for 20, 22 and 29 July. 23 June Banks and building societies are summoned for a meeting with Jeremy Hunt as pressure grows on them to help people struggling with rising mortgage costs. A series of measures are agreed, offering more flexibility. Junior doctors in England announce a new five-day walkout from 13 to 18 July – the longest strike yet – over pay. Following a trial at Northampton Crown Court, Louis De Zoysa is convicted of the 2020 murder of police sergeant Matt Ratana. 24 June – The UK government holds an emergency COBRA meeting to discuss the Wagner Group rebellion in Russia. Sunak urges both sides to "be responsible and to protect civilians". 25 June A national technical fault affects the 999 service, meaning emergency services are unable to receive calls for around two hours. The service is fully restored by the evening. A spokesman for Sarah, Duchess of York says that she is recovering following surgery for breast cancer at King Edward VII's Hospital a few days earlier.

Computational proteomics is both an interdisciplinary field and a specialization of bioinformatics which uses computational techniques to study the proteome; in particular, computational proteomics is based on peptides identification techniques and allows to integrate vast quantities of heterogeneous data referred to proteins (e.g., identification of proteins, quantification, protein-protein interactions, structures...) and genomics (e.g., expression of genes and expression of proteins). The results of both proteomics and computational proteomics are used by biomedical engineering, biotechnology and Agri-Food Studies.

Originally, the term radiation protection referred only to ionizing radiation. Today, non-ionizing radiation is also included and is the responsibility of the Federal Office for Radiation Protection, the Radiation Protection Division of the Federal Office of Public Health and the Ministry of Climate Action and Energy (Austria). The project collected, evaluated and compared data on the legal situation in all European countries (47 countries plus Germany) and major non-European countries (China, India, Australia, Japan, Canada, New Zealand and the USA) regarding electric, magnetic and electromagnetic fields (EMF) and optical radiation (OS). The results were very different and in some cases deviated from the recommendations of the International Commission on Non-Ionizing Radiation Protection (ICNIRP).

The size of a burn is measured as a percentage of total body surface area (TBSA) affected by partial thickness or full thickness burns. First-degree burns that are only red in color and are not blistering are not included in this estimation. Most burns (70%) involve less than 10% of the TBSA. Unit of measuring burns is VSD as 10% TBSA is equal to 1VSD. There are a number of methods to determine the TBSA, including the Wallace rule of nines, Lund and Browder chart, and estimations based on a person's palm size. The rule of nines is easy to remember but only accurate in people over 16 years of age. More accurate estimates can be made using Lund and Browder charts, which take into account the different proportions of body parts in adults and children. The size of a person's handprint (including the palm and fingers) is approximately 1% of their TBSA.

Sources: en.wikipedia.org

Frequently asked questions